CXM. DD Sheet. Nice looking upturn:
Announced 10-10-2011 that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen™ professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds..
http://ih.advfn.com/p.php?pid=nmona&article=49480240
Generx®
Angiogenic Therapy PDF 10-18-2011
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDQzNDYzfENoaWxkSUQ9NDY2MDYwfFR5cGU9MQ==&t=1
Seeking AlPha - Buy rating:
http://seekingalpha.com/article/298799-buy-and-sell-ideas-based-on-monday-s-big-biotech-news-movers?source=yahoo
A full PipeLine of Drugs: Home Website:
http://www.cardiumthx.com/index.html
The Big Ticket Winner is still ahead of them:
An adenovector construct carrying the angiogenic gene FGF-4
Affecting the mid-size to smaller blood vessels deeper within the heart muscle.
A line of Skin Care & Supplements: MEDPODIUM:
http://www.medpodium.com/
10-Q [8-15-2011]
200,000,000 shares authorized; issued and outstanding 83,097,967 at June 30, 2011 and December 31, 2010 Float N/A.
"We anticipate that negative cash flow from operations will continue for 2011. Although we believe that we have sufficient capital to support our operations through January 1, 2012,"
"As of June 30, 2011, we had $3,182,919 in cash and cash equivalents and $1,325,000 in restricted cash"
http://ih.advfn.com/p.php?pid=nmona&article=48838354
iHub: http://ih.advfn.com/p.php?pid=squote&symbol=CXM
Generx Cardio-Chant Drug, Not Surgery based Treatment
for cardio vascular disease: a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease.
Announced 10-10-2011 that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen™ professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds..
http://ih.advfn.com/p.php?pid=nmona&article=49480240
Generx®
Angiogenic Therapy PDF 10-18-2011
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDQzNDYzfENoaWxkSUQ9NDY2MDYwfFR5cGU9MQ==&t=1
Seeking AlPha - Buy rating:
http://seekingalpha.com/article/298799-buy-and-sell-ideas-based-on-monday-s-big-biotech-news-movers?source=yahoo
A full PipeLine of Drugs: Home Website:
http://www.cardiumthx.com/index.html
The Big Ticket Winner is still ahead of them:
An adenovector construct carrying the angiogenic gene FGF-4
Affecting the mid-size to smaller blood vessels deeper within the heart muscle.
A line of Skin Care & Supplements: MEDPODIUM:
http://www.medpodium.com/
10-Q [8-15-2011]
200,000,000 shares authorized; issued and outstanding 83,097,967 at June 30, 2011 and December 31, 2010 Float N/A.
"We anticipate that negative cash flow from operations will continue for 2011. Although we believe that we have sufficient capital to support our operations through January 1, 2012,"
"As of June 30, 2011, we had $3,182,919 in cash and cash equivalents and $1,325,000 in restricted cash"
http://ih.advfn.com/p.php?pid=nmona&article=48838354
iHub: http://ih.advfn.com/p.php?pid=squote&symbol=CXM
Generx Cardio-Chant Drug, Not Surgery based Treatment
for cardio vascular disease: a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease.
Whup Whup. Signature Board. "A Dawgg".
http://investorshub.advfn.com/boards/board.aspx?board_id=21519
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
